Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 07 February 2017 | By Zachary Brennan
The US Federal Trade Commission (FTC) on Tuesday filed a complaint against Shire ViroPharma for blocking and delaying the marketing of generic versions of its antibiotic Vancocin (vancomycin), which first won FDA approval in 1986.
“Facing the threat of generic competition to its lucrative franchise, ViroPharma inundated the FDA with regulatory and court filings—forty-six in all—to delay the FDA’s approval of generic Vancocin Capsules. That number is, by far, the most filings that any firm has ever made to the FDA concerning a single drug product,” FTC said in its complaint.
Shire ViroPharma (Shire acquired ViroPharma in 2013 for $4.2 billion) bought Vancocin, which is indicated to treat Clostridium difficile-associated diarrhea, from Eli Lilly in November 2004.
According to FTC, from 2004 to 2011, Vancocin was ViroPharma’s largest revenue generating product, accounting for all of the company’s total net revenues until 2009 and up to 53% of the company’s total net revenues in 2011.
US sales of Vancocin grew from about $40 million in 2003 to almost $300 million by 2011.
Between March 2006 and April 2012, ViroPharma made at least 43 submissions to FDA and initiated three more proceedings in federal court to obstruct and delay the approval of generics, via:
Tags: Vancocin, c. difficile, Eli Lilly, Shire, citizen petitions